Phase 3Completed
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. (Industry)
- Enrollment
- 3 enrolled
- Conditions
- Treatment-naїve Mantle Cell Lymphoma
- Interventions
- Orelabrutinib and R-CHOP; R-CHOP
- Ages
- adults, older adults
- Registry
- NCT05051891
Full record on ClinicalTrials.gov
From the registry
To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.
Primary outcomes
- PFS
History
Last registry update
Primary completion
Started
Registered